Home
·
Merck Group
·
Contact
·
Deutsch
·
Sitemap
·
Search
Sitemap
Merck 2009 at a glance
Development 2000-2009
About Merck
History
Today and the future
Executive Board
Financial calendar
Letter from
Karl-Ludwig Kley
Corporate governance
Corporate governance report
Merck KGaA
Remuneration and ownership of shares
Corporate governance practices
Procedures of the corporate bodies
Executive Board
Supervisory Board
Board of Partners of E. Merck KG
Report of the Supervisory Board
Merck shares
Share price development
Share data
Estimates
Shareholder structure
Information on capital and shares
Management Report
Economic situation
Financial position and results of operations
Business development
Regions
Acquisitions
Business sectors
Free cash flow
Key financial performance indicators
Total assets
Capital spending
Value added
Responsibility
Employees
Environment and safety
Community
Corporate and Other
Risk report
Business-related risks
Financial risks
Rating
Legal risks
Human resource risks
Other risks
Report on expected developments
Global economy
Merck
Pharmaceuticals
Chemicals
Subsequent events
Pharmaceuticals
Merck Serono
Business development
Regions
Therapeutic areas
Oncology
Neurodegenerative Diseases
Autoimmune and Inflammatory Diseases
Fertility
Endocrinology
CardioMetabolic Care
Research and development
Overview compounds
Cooperations
Oncology
Neurodegenerative Diseases
Fertility
Autoimmune and Inflammatory Diseases
Endocrinology
Consumer Health Care
Business development
Brands
Regions
Chemicals
Liquid Crystals
Business development
New technologies
Research and development
Performance & Life Science Chemicals
Business development
Regions
Laboratory Business
Life Science Solutions
Pigments
Financial Statements
Income Statement
Balance Sheet
Segment Reporting
Divisions
Regions
Cash Flow Statement
Free Cash Flow
Comprehensive Income
Changes in Net Equity
Notes
Scope of consolidation
Accounting policies
Notes to the income statement
Sales
Royalty and commission income
Cost of sales
Marketing and selling expenses
Administration expenses
Other operating expenses and income
Research and development
Amortization of intangible assets
Investment result
Exceptional items
Financial result
Income tax
Minority interest
Earnings per share
Notes to the balance sheet
Cash and cash equivalents
Marketable securities
Trade accounts receivable
Inventories
Other assets
Tax receivables
Intangible assets
Property, plant and equipment
Investments at equity
Non-current financial assets
Financial liabilities
Trade accounts payable
Other liabilities
Tax liabilities
Provisions
Provisions for pensions
Net equity
Notes to the segment reporting
Notes to the cash flow statement
Net cash flows from operating activities
Net cash flows from investing activities
Net cash flows from financing activities
Cash and cash equivalents
Free cash flow
Other disclosures
Derivative financial instruments
Management of financial risks
Other disclosures on financial instruments
Contingent liabilities
Other financial obligations
Personnel expenses
Material costs
Auditors' fees
Corporate governance
Companies opting for exemption
Related-party disclosures
Compensation of the corporate bodies
Preparation and approval
Auditor's Report
SERVICES
Recommend page
Print page
Order online
Glossary
Downloads
CHART GENERATOR
Important key figures
Merck 2009 at a glance
Letter from
Karl-Ludwig Kley
Corporate governance
Merck shares
Management Report
Pharmaceuticals
Chemicals
Financial Statements
Notes
made by Nexxar - your next annual report online!, Vienna - Austria
